Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Nine RNAi-Related Patent Applications, November 2007

Premium
Title: siRNA Targeting Myelocytomatosis Viral Oncogene Homolog
 
Number: 20070255052
 
Filed: June 14, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MYC.”
 

 
Title: siRNA Targeting Serine/Threonine Kinase 22B
 
Number: 20070255051
 
Filed: June 12, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to STK22B.”
 

 
Title: siRNA Targeting Minichromosome Maintenance Deficient 2, Mitotin
 
Number: 20070255050
 
Filed: June 6, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MCM2.”
 

 
Title: siRNA Targeting EPH Receptor A3
 
Number: 20070255049
 
Filed: June 5, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EPHA3.”
 

 
Title: siRNA Targeting Discoidin Domain Receptor Family, Member 1
 
Number: 20070255048
 
Filed: June 1, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to DDR1.”
 

 
Title: siRNA Targeting Cell Division Cycle 6 Homolog
 
Number: 20070255047
 
Filed: May 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDC6.”
 

 
Title: siRNA Targeting Spectrin SH3 Domain Binding Protein 1
 
Number: 20070255046
 
Filed: April 4, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to SSH3BP1.”
 

 
Title: Methods for Treating and Preventing Apoptosis-Related Diseases Using RNA Interfering Agents
 
Number: 20070254850
 
Filed: Oct. 30, 2003 PCT Filed: Oct. 30, 2003
 
Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)
 
According to the patent application’s abstract, the invention is “based, at least in part, on the discovery of compositions and methods useful in the modulation, e.g., inhibition, of gene expression or protein activity. In particular, the … invention is based on novel RNA interfering agents, e.g., siRNA molecules which target apoptosis-related genes or pro-inflammatory cytokines, and result in reduction, e.g., prolonged reduction, of apoptosis-related gene expression or proinflammatory cytokine expression in cells.
 
“Inhibition of apoptosis-related gene expression or protein activity or pro-inflammatory cytokine expression or protein activity, e.g., by the siRNAs of the invention, inhibits apoptosis-mediated diseases or disorders and pro-inflammatory cytokine mediated diseases or disorders, including, for example, transplant rejection, hepatitis, liver injury, sepsis, and cancer,” the abstract adds.
 

 
Title: Compositions and Methods Employing Universal-Binding Nucleotides for Targeting Multiple Gene Variants with a Single siRNA Duplex
 
Number: 20070254362
 
Filed: Dec. 13, 2006
 
Lead Inventor: Steven Quay, Nastech Pharmaceutical
 

The patent application, its abstract states, claims “siRNA molecules of between about 15 base-pairs and about 40 base-pairs comprising one or more universal-binding nucleotide such as inosine, 1-beta-D-ribofuranosyl-5-nitroindole, and 1-beta-D-ribofuranosyl-3-nitropyrrole, compositions comprising one or more universal-binding nucleotide comprising siRNA, and methods for making and for using such universal-binding nucleotide comprising siRNA molecules to increase the specific binding of the modified siRNA molecule to variants of a target sequence such as, for example, when in contact with a biological sample and to reduce off-target effects of the siRNA molecule.”